O	0	3	Pro	Pro	NN	B-NP
O	3	4	/	/	SYM	I-NP
O	4	15	antioxidant	antioxidant	NN	I-NP
O	16	22	status	status	NN	I-NP
O	23	26	and	and	CC	O
O	27	29	AP	AP	NN	B-NP
O	29	30	-	-	HYPH	B-NP
O	30	31	1	1	CD	I-NP
O	32	45	transcription	transcription	NN	I-NP
O	46	52	factor	factor	NN	I-NP
O	53	55	in	in	IN	B-PP
O	56	62	murine	murine	JJ	B-NP
B-Organ	63	67	skin	skin	NN	I-NP
O	68	77	following	follow	VBG	B-PP
O	78	85	topical	topical	JJ	B-NP
O	86	94	exposure	exposure	NN	I-NP
O	95	97	to	to	TO	B-PP
O	98	104	cumene	cumene	NN	B-NP
O	105	118	hydroperoxide	hydroperoxide	NN	I-NP
O	118	119	.	.	.	O

O	121	128	Organic	Organic	JJ	B-NP
O	129	138	peroxides	peroxide	NNS	I-NP
O	138	139	,	,	,	O
O	140	146	widely	widely	RB	B-VP
O	147	151	used	use	VBN	I-VP
O	152	154	in	in	IN	B-PP
O	155	158	the	the	DT	B-NP
O	159	167	chemical	chemical	NN	I-NP
O	168	171	and	and	CC	I-NP
O	172	186	pharmaceutical	pharmaceutical	JJ	I-NP
O	187	197	industries	industry	NNS	I-NP
O	197	198	,	,	,	O
O	199	202	can	can	MD	B-VP
O	203	206	act	act	VB	I-VP
O	207	209	as	as	IN	B-PP
B-Cancer	210	214	skin	skin	NN	B-NP
I-Cancer	215	220	tumor	tumor	NN	I-NP
O	221	230	promoters	promoter	NNS	I-NP
O	231	234	and	and	CC	O
O	235	240	cause	cause	VB	B-VP
B-Pathological_formation	241	250	epidermal	epidermal	JJ	B-NP
I-Pathological_formation	251	262	hyperplasia	hyperplasia	NN	I-NP
O	262	263	.	.	.	O

O	264	268	They	They	PRP	B-NP
O	269	272	are	be	VBP	B-VP
O	273	277	also	also	RB	I-VP
O	278	283	known	know	VBN	I-VP
O	284	286	to	to	TO	I-VP
O	287	294	trigger	trigger	VB	I-VP
O	295	299	free	free	JJ	B-NP
O	300	307	radical	radical	NN	I-NP
O	308	318	generation	generation	NN	I-NP
O	318	319	.	.	.	O

O	320	323	The	The	DT	B-NP
O	324	331	present	present	JJ	I-NP
O	332	337	study	study	NN	I-NP
O	338	347	evaluated	evaluate	VBD	B-VP
O	348	351	the	the	DT	B-NP
O	352	358	effect	effect	NN	I-NP
O	359	361	of	of	IN	B-PP
O	362	368	cumene	cumene	NN	B-NP
O	369	382	hydroperoxide	hydroperoxide	NN	I-NP
O	383	384	(	(	(	O
O	384	387	Cum	Cum	NN	B-NP
O	387	388	-	-	HYPH	O
O	388	391	OOH	OOH	NN	B-NP
O	391	392	)	)	)	O
O	393	395	on	on	IN	B-PP
O	396	399	the	the	DT	B-NP
O	400	409	induction	induction	NN	I-NP
O	410	412	of	of	IN	B-PP
O	413	422	activator	activator	NN	B-NP
O	423	430	protein	protein	NN	I-NP
O	430	431	-	-	HYPH	B-NP
O	431	432	1	1	CD	I-NP
O	433	434	(	(	(	O
O	434	436	AP	AP	NN	B-NP
O	436	437	-	-	HYPH	B-NP
O	437	438	1	1	CD	I-NP
O	438	439	)	)	)	O
O	439	440	,	,	,	O
O	441	446	which	which	WDT	B-NP
O	447	449	is	be	VBZ	B-VP
O	450	456	linked	link	VBN	I-VP
O	457	459	to	to	TO	B-PP
O	460	463	the	the	DT	B-NP
O	464	474	expression	expression	NN	I-NP
O	475	477	of	of	IN	B-PP
O	478	483	genes	gene	NNS	B-NP
O	484	494	regulating	regulate	VBG	B-VP
B-Cell	495	499	cell	cell	NN	B-NP
O	500	513	proliferation	proliferation	NN	I-NP
O	513	514	,	,	,	O
O	515	521	growth	growth	NN	B-NP
O	522	525	and	and	CC	I-NP
O	526	540	transformation	transformation	NN	I-NP
O	540	541	.	.	.	O

O	542	552	Previously	Previously	RB	B-ADVP
O	552	553	,	,	,	O
O	554	556	we	we	PRP	B-NP
O	557	565	reported	report	VBD	B-VP
O	566	570	that	that	IN	B-SBAR
O	571	578	topical	topical	JJ	B-NP
O	579	587	exposure	exposure	NN	I-NP
O	588	590	to	to	TO	B-PP
O	591	594	Cum	Cum	NN	B-NP
O	594	595	-	-	HYPH	B-NP
O	595	598	OOH	OOH	NN	I-NP
O	599	605	caused	cause	VBD	B-VP
O	606	615	formation	formation	NN	B-NP
O	616	618	of	of	IN	B-PP
O	619	623	free	free	JJ	B-NP
O	624	632	radicals	radical	NNS	I-NP
O	633	636	and	and	CC	O
O	637	646	oxidative	oxidative	JJ	B-NP
O	647	653	stress	stress	NN	I-NP
O	654	656	in	in	IN	B-PP
O	657	660	the	the	DT	B-NP
B-Organ	661	665	skin	skin	NN	I-NP
O	666	668	of	of	IN	B-PP
O	669	676	vitamin	vitamin	NN	B-NP
O	677	678	E	E	NN	I-NP
O	678	679	-	-	HYPH	B-NP
O	679	688	deficient	deficient	JJ	I-NP
O	689	693	mice	mouse	NNS	I-NP
O	693	694	.	.	.	O

O	695	698	The	The	DT	B-NP
O	699	706	present	present	JJ	I-NP
O	707	712	study	study	NN	I-NP
O	713	717	used	use	VBD	B-VP
B-Cell	718	721	JB6	JB6	NN	B-NP
I-Cell	722	723	P	P	NN	I-NP
I-Cell	723	724	+	+	SYM	B-NP
I-Cell	725	730	mouse	mouse	NN	I-NP
I-Cell	731	740	epidermal	epidermal	JJ	I-NP
I-Cell	741	746	cells	cell	NNS	I-NP
O	747	750	and	and	CC	O
O	751	753	AP	AP	NN	B-NP
O	753	754	-	-	HYPH	B-NP
O	754	755	1	1	CD	I-NP
O	755	756	-	-	HYPH	I-NP
O	756	766	luciferase	luciferase	NN	I-NP
O	767	775	reporter	reporter	NN	I-NP
O	776	786	transgenic	transgenic	JJ	I-NP
O	787	791	mice	mouse	NNS	I-NP
O	792	794	to	to	TO	B-VP
O	795	803	identify	identify	VB	I-VP
O	804	811	whether	whether	IN	B-SBAR
O	812	820	exposure	exposure	NN	B-NP
O	821	823	to	to	TO	B-PP
O	824	827	Cum	Cum	NN	B-NP
O	827	828	-	-	HYPH	B-NP
O	828	831	OOH	OOH	NN	I-NP
O	832	838	caused	cause	VBD	B-VP
O	839	849	activation	activation	NN	B-NP
O	850	852	of	of	IN	B-PP
O	853	855	AP	AP	NN	B-NP
O	855	856	-	-	HYPH	B-NP
O	856	857	1	1	CD	I-NP
O	857	858	,	,	,	O
O	859	868	oxidative	oxidative	JJ	B-NP
O	869	875	stress	stress	NN	I-NP
O	875	876	,	,	,	O
O	877	886	depletion	depletion	NN	B-NP
O	887	889	of	of	IN	B-PP
O	890	902	antioxidants	antioxidant	NNS	B-NP
O	903	906	and	and	CC	O
B-Cancer	907	912	tumor	tumor	NN	B-NP
O	913	922	formation	formation	NN	I-NP
O	923	929	during	during	IN	B-PP
O	930	933	two	two	CD	B-NP
O	933	934	-	-	HYPH	I-NP
O	934	939	stage	stage	NN	I-NP
O	940	954	carcinogenesis	carcinogenesis	NN	I-NP
O	954	955	.	.	.	O

O	956	958	In	In	FW	B-NP
O	959	964	vitro	vitro	FW	I-NP
O	965	972	studies	study	NNS	I-NP
O	973	978	found	find	VBD	B-VP
O	979	983	that	that	IN	B-SBAR
O	984	992	exposure	exposure	NN	B-NP
O	993	995	to	to	TO	B-PP
O	996	999	Cum	Cum	NN	B-NP
O	999	1000	-	-	HYPH	B-NP
O	1000	1003	OOH	OOH	NN	I-NP
O	1004	1011	reduced	reduce	VBD	B-VP
O	1012	1015	the	the	DT	B-NP
O	1016	1021	level	level	NN	I-NP
O	1022	1024	of	of	IN	B-PP
O	1025	1036	glutathione	glutathione	NN	B-NP
O	1037	1038	(	(	(	O
O	1038	1041	GSH	GSH	NN	B-NP
O	1041	1042	)	)	)	O
O	1043	1045	in	in	IN	B-PP
O	1046	1051	mouse	mouse	NN	B-NP
B-Cell	1052	1061	epidermal	epidermal	JJ	I-NP
I-Cell	1062	1067	cells	cell	NNS	I-NP
O	1068	1069	(	(	(	O
B-Cell	1069	1072	JB6	JB6	NN	B-NP
I-Cell	1073	1074	P	P	NN	I-NP
I-Cell	1074	1075	+	+	SYM	B-NP
O	1075	1076	)	)	)	O
O	1077	1080	and	and	CC	O
O	1081	1087	caused	cause	VBD	B-VP
O	1088	1091	the	the	DT	B-NP
O	1092	1101	induction	induction	NN	I-NP
O	1102	1104	of	of	IN	B-PP
O	1105	1107	AP	AP	NN	B-NP
O	1107	1108	-	-	HYPH	B-NP
O	1108	1109	1	1	CD	I-NP
O	1109	1110	.	.	.	O

O	1111	1115	Mice	Mouse	NNS	B-NP
O	1116	1122	primed	prim	VBN	B-VP
O	1123	1127	with	with	IN	B-PP
O	1128	1136	dimethyl	dimethyl	NN	B-NP
O	1136	1137	-	-	HYPH	B-NP
O	1137	1141	benz	benz	NN	I-NP
O	1141	1142	[	[	(	O
O	1142	1143	a	a	DT	O
O	1143	1144	]	]	)	O
O	1144	1154	anthracene	anthracene	NN	B-NP
O	1155	1156	(	(	(	O
O	1156	1160	DMBA	DMBA	NN	B-NP
O	1160	1161	)	)	)	O
O	1162	1166	were	be	VBD	B-VP
O	1167	1176	topically	topically	RB	I-VP
O	1177	1184	exposed	expose	VBN	I-VP
O	1185	1187	to	to	TO	B-PP
O	1188	1191	Cum	Cum	NN	B-NP
O	1191	1192	-	-	HYPH	O
O	1192	1195	OOH	OOH	NN	B-NP
O	1196	1197	(	(	(	O
O	1197	1199	82	82	CD	B-NP
O	1199	1200	.	.	.	O
O	1200	1201	6	6	CD	B-NP
O	1202	1210	micromol	micromol	NN	I-NP
O	1210	1211	)	)	)	O
O	1212	1214	or	or	CC	O
O	1215	1218	the	the	DT	B-NP
O	1219	1227	positive	positive	JJ	I-NP
O	1228	1235	control	control	NN	I-NP
O	1235	1236	,	,	,	O
O	1237	1239	12	12	CD	B-NP
O	1239	1240	-	-	HYPH	I-NP
O	1240	1241	O	O	NN	I-NP
O	1241	1242	-	-	HYPH	B-NP
O	1242	1262	tetradecanoylphorbol	tetradecanoylphorbol	NN	I-NP
O	1262	1263	-	-	HYPH	B-NP
O	1263	1265	13	13	CD	I-NP
O	1265	1266	-	-	HYPH	I-NP
O	1266	1273	acetate	acetate	NN	I-NP
O	1274	1275	(	(	(	O
O	1275	1278	TPA	TPA	NN	B-NP
O	1278	1279	,	,	,	O
O	1280	1282	17	17	CD	B-NP
O	1283	1287	nmol	nmol	NN	I-NP
O	1287	1288	)	)	)	O
O	1288	1289	,	,	,	O
O	1290	1295	twice	twice	RB	B-ADJP
O	1296	1302	weekly	weekly	JJ	I-ADJP
O	1303	1306	for	for	IN	B-PP
O	1307	1309	29	29	CD	B-NP
O	1310	1315	weeks	week	NNS	I-NP
O	1315	1316	.	.	.	O

O	1317	1327	Activation	Activation	NN	B-NP
O	1328	1330	of	of	IN	B-PP
O	1331	1333	AP	AP	NN	B-NP
O	1333	1334	-	-	HYPH	B-NP
O	1334	1335	1	1	CD	I-NP
O	1336	1338	in	in	IN	B-PP
B-Organ	1339	1343	skin	skin	NN	B-NP
O	1344	1347	was	be	VBD	B-VP
O	1348	1356	detected	detect	VBN	I-VP
O	1357	1359	as	as	RB	B-ADVP
O	1360	1365	early	early	RB	I-ADVP
O	1366	1368	as	as	IN	B-PP
O	1369	1370	2	2	CD	B-NP
O	1371	1376	weeks	week	NNS	I-NP
O	1377	1386	following	follow	VBG	B-PP
O	1387	1390	Cum	Cum	NN	B-NP
O	1390	1391	-	-	HYPH	B-NP
O	1391	1394	OOH	OOH	NN	I-NP
O	1395	1397	or	or	CC	I-NP
O	1398	1401	TPA	TPA	NN	I-NP
O	1402	1410	exposure	exposure	NN	I-NP
O	1410	1411	.	.	.	O

O	1412	1414	No	No	DT	B-NP
O	1415	1417	AP	AP	NN	I-NP
O	1417	1418	-	-	HYPH	B-NP
O	1418	1419	1	1	CD	I-NP
O	1420	1430	expression	expression	NN	I-NP
O	1431	1434	was	be	VBD	B-VP
O	1435	1440	found	find	VBN	I-VP
O	1441	1443	19	19	CD	B-NP
O	1444	1449	weeks	week	NNS	I-NP
O	1450	1455	after	after	IN	B-PP
O	1456	1466	initiation	initiation	NN	B-NP
O	1466	1467	.	.	.	O

B-Pathological_formation	1468	1477	Papilloma	Papilloma	NN	B-NP
O	1478	1487	formation	formation	NN	I-NP
O	1488	1491	was	be	VBD	B-VP
O	1492	1500	observed	observe	VBN	I-VP
O	1501	1503	in	in	IN	B-PP
O	1504	1508	both	both	CC	O
O	1509	1512	the	the	DT	B-NP
O	1513	1517	DMBA	DMBA	NN	I-NP
O	1517	1518	-	-	HYPH	B-NP
O	1518	1521	TPA	TPA	NN	I-NP
O	1521	1522	-	-	HYPH	B-NP
O	1523	1526	and	and	CC	I-NP
O	1527	1531	DMBA	DMBA	NN	I-NP
O	1531	1532	-	-	HYPH	I-NP
O	1532	1535	Cum	Cum	NN	I-NP
O	1535	1536	-	-	HYPH	I-NP
O	1536	1539	OOH	OOH	NN	I-NP
O	1539	1540	-	-	HYPH	B-NP
O	1540	1547	exposed	expose	VBN	I-NP
O	1548	1555	animals	animal	NNS	I-NP
O	1555	1556	,	,	,	O
O	1557	1564	whereas	whereas	IN	O
B-Cancer	1565	1569	skin	skin	NN	B-NP
I-Cancer	1570	1580	carcinomas	carcinoma	NNS	I-NP
O	1581	1585	were	be	VBD	B-VP
O	1586	1591	found	find	VBN	I-VP
O	1592	1596	only	only	RB	B-PP
O	1597	1599	in	in	IN	I-PP
O	1600	1603	the	the	DT	B-NP
O	1604	1608	DMBA	DMBA	NN	I-NP
O	1608	1609	-	-	HYPH	B-NP
O	1609	1612	Cum	Cum	NN	I-NP
O	1612	1613	-	-	HYPH	B-NP
O	1613	1616	OOH	OOH	NN	I-NP
O	1616	1617	-	-	HYPH	B-NP
O	1617	1624	treated	treat	VBN	I-NP
O	1625	1629	mice	mouse	NNS	I-NP
O	1629	1630	.	.	.	O

O	1631	1632	A	A	DT	B-NP
O	1633	1640	greater	great	JJR	I-NP
O	1641	1653	accumulation	accumulation	NN	I-NP
O	1654	1656	of	of	IN	B-PP
O	1657	1669	peroxidative	peroxidative	JJ	B-NP
O	1670	1678	products	product	NNS	I-NP
O	1679	1680	(	(	(	O
O	1680	1694	thiobarbituric	thiobarbituric	JJ	B-NP
O	1695	1699	acid	acid	NN	I-NP
O	1699	1700	-	-	HYPH	B-NP
O	1700	1708	reactive	reactive	JJ	I-NP
O	1709	1719	substances	substance	NNS	I-NP
O	1719	1720	)	)	)	O
O	1720	1721	,	,	,	O
O	1722	1734	inflammation	inflammation	NN	B-NP
O	1735	1738	and	and	CC	O
O	1739	1748	decreased	decrease	VBD	B-VP
O	1749	1755	levels	level	NNS	B-NP
O	1756	1758	of	of	IN	B-PP
O	1759	1762	GSH	GSH	NN	B-NP
O	1763	1766	and	and	CC	O
O	1767	1772	total	total	JJ	B-NP
O	1773	1784	antioxidant	antioxidant	JJ	I-NP
O	1785	1793	reserves	reserve	NNS	I-NP
O	1794	1798	were	be	VBD	B-VP
O	1799	1803	also	also	RB	I-VP
O	1804	1812	observed	observe	VBN	I-VP
O	1813	1815	in	in	IN	B-PP
O	1816	1819	the	the	DT	B-NP
B-Organ	1820	1824	skin	skin	NN	I-NP
O	1825	1827	of	of	IN	B-PP
O	1828	1832	DMBA	DMBA	NN	B-NP
O	1832	1833	-	-	HYPH	B-NP
O	1833	1836	Cum	Cum	NN	I-NP
O	1836	1837	-	-	HYPH	B-NP
O	1837	1840	OOH	OOH	NN	I-NP
O	1840	1841	-	-	HYPH	B-NP
O	1841	1848	exposed	expose	VBN	I-NP
O	1849	1853	mice	mouse	NNS	I-NP
O	1853	1854	.	.	.	O

O	1855	1860	These	These	DT	B-NP
O	1861	1868	results	result	NNS	I-NP
O	1869	1876	suggest	suggest	VBP	B-VP
O	1877	1881	that	that	IN	B-SBAR
O	1882	1885	Cum	Cum	NN	B-NP
O	1885	1886	-	-	HYPH	B-NP
O	1886	1889	OOH	OOH	NN	I-NP
O	1889	1890	-	-	HYPH	B-NP
O	1890	1897	induced	induce	VBN	I-NP
O	1898	1912	carcinogenesis	carcinogenesis	NN	I-NP
O	1913	1915	is	be	VBZ	B-VP
O	1916	1927	accompanied	accompany	VBN	I-VP
O	1928	1930	by	by	IN	B-PP
O	1931	1940	increased	increase	VBN	B-NP
O	1941	1943	AP	AP	NN	I-NP
O	1943	1944	-	-	HYPH	B-NP
O	1944	1945	1	1	CD	I-NP
O	1946	1956	activation	activation	NN	I-NP
O	1957	1960	and	and	CC	O
O	1961	1968	changes	change	NNS	B-NP
O	1969	1971	in	in	IN	B-PP
O	1972	1983	antioxidant	antioxidant	JJ	B-NP
O	1984	1990	status	status	NN	I-NP
O	1990	1991	.	.	.	O

